RxDoctor Payments Data

Marcus Urey, MD

Advanced Heart Failure and Transplant Cardiology · San Diego, CANPI 1972820058

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (59.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 38.8% of the total. Among advanced heart failure and transplant cardiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$340,945in general payments, 2019–2025

Across 403 payments — averaging $846.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$132K
  • AstraZeneca$84K
  • Bridgebio Pharma, Inc.$44K
  • Pfizer$42K
  • Akcea Therapeutics, Inc.$19K
  • Edwards Lifesciences$13K
  • plus $8K from 11 others
$575,994in research payments, 2019–2025

Across 47 payments — averaging $12,255 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ionis Pharmaceuticals, Inc.$343K
  • E.r. Squibb & Sons, L.L.C.$187K
  • Alnylam Pharmaceuticals Inc.$28K
  • AstraZeneca$17K
$69,999in ownership & investment interests, 2019–2025

Across 2 payments — averaging $35,000 each. An ownership or investment interest held by the physician or an immediate family member.

  • Vektor Medical Inc.$70K

What the payments were for

  • Consulting fees$80,45124%
  • Speaking & faculty fees$203,19060%
  • Travel & lodging$43,73413%
  • Food & beverage$13,5624%
  • Education$70%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$340,945 in reported general payments places this provider in the 95th percentile of 111 advanced heart failure and transplant cardiology providers in California.

See all advanced heart failure and transplant cardiology providers in California

Medicare billing

Part B allowed, 2024
$118,763
Medicare patients
351
Services billed
1,233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis353$8,549,919
VyndaqelTafamidis Meglumine43$872,902
WainuaEplontersen Sodium12$429,579
JardianceEmpagliflozin336$338,714
ArcalystRilonacept13$304,430
EntrestoSacubitril/Valsartan139$186,009
EliquisApixaban173$149,726
FarxigaDapagliflozin Propanediol115$100,687
TrulicityDulaglutide75$74,748
Sirolimus193$61,329
Envarsus XrTacrolimus86$47,680
VeltassaPatiromer Calcium Sorbitex30$34,490
XareltoRivaroxaban17$22,516
Everolimus11$17,119
OzempicSemaglutide19$16,779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel, Eliquis$41,510$9,572,547569 claims
AstraZenecaWainua, Farxiga$83,526$530,266127 claims
Boehringer IngelheimJardiance$124$338,714336 claims
Johnson & JohnsonXarelto$19$22,51617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 111 advanced heart failure and transplant cardiology providers in California.

Other advanced heart failure and transplant cardiology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →